title: Prophylactic treatment with a G glycoprotein monoclonal antibody reduces pulmonary inflammation in respiratory syncytial virus (RSV)-challenged naive and formalin-inactivated RSV-immunized BALB/c mice.
abstract: We examined whether prophylactically administered anti-respiratory syncytial virus (anti-RSV) G monoclonal antibody (MAb) would decrease the pulmonary inflammation associated with primary RSV infection and formalin-inactivated RSV (FI-RSV)-enhanced disease in mice. MAb 131-2G administration 1 day prior to primary infection reduced the pulmonary inflammatory response and the level of RSV replication. Further, intact or F(ab')(2) forms of MAb 131-2G administered 1 day prior to infection in FI-RSV-vaccinated mice reduced enhanced inflammation and disease. This study shows that an anti-RSV G protein MAb might provide prophylaxis against both primary infection and FI-RSV-associated enhanced disease. It is possible that antibodies with similar reactivities might prevent enhanced disease and improve the safety of nonlive virus vaccines.
authors.affiliation: Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, 1600 Clifton Rd. NE, Mailstop G-18, Atlanta, GA 30333, USA.
authors.forename: Gertrud U
authors.initials: GU
authors.lastname: Radu
authors.forename: Hayat
authors.initials: H
authors.lastname: Caidi
authors.forename: Congrong
authors.initials: C
authors.lastname: Miao
authors.forename: Ralph A
authors.initials: RA
authors.lastname: Tripp
authors.forename: Larry J
authors.initials: LJ
authors.lastname: Anderson
authors.forename: Lia M
authors.initials: LM
authors.lastname: Haynes
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use*; D000914:Antibodies, Viral / Q000276:immunology / Q000627:therapeutic use*; D001835:Body Weight; D001992:Bronchoalveolar Lavage Fluid / Q000737:chemistry / Q000166:cytology; D018890:Chemoprevention / Q000379:methods*; D051379:Mice; D008807:Mice, Inbred BALB C; D011014:Pneumonia / Q000276:immunology / Q000473:pathology / Q000517:prevention & control*; D018357:Respiratory Syncytial Virus Infections / Q000276:immunology / Q000473:pathology / Q000517:prevention & control*; D022261:Respiratory Syncytial Virus Vaccines / Q000276:immunology*; D012136:Respiratory Syncytial Viruses / Q000276:immunology / Q000472:pathogenicity; D015164:Vaccines, Inactivated / Q000276:immunology; D014760:Viral Fusion Proteins / Q000276:immunology*; D019562:Viral Load
chemical_list: D000911:Antibodies, Monoclonal; D000914:Antibodies, Viral; C502275:G glycoprotein, Respiratory syncytial virus; D022261:Respiratory Syncytial Virus Vaccines; D015164:Vaccines, Inactivated; D014760:Viral Fusion Proteins